3rd Annual Meeting Programme

VALIDATE 3rd Annual Meeting Programme

Tuesday 1 October 2019 (full day)

[0900-1000 Closed Network Management Board Meeting in Boardroom 2]

In The Grand Hall - All delegates

0915 Registration and tea/coffee

1010 Prof Helen McShane

VALIDATE Director, University of Oxford

Welcome

1020 Samantha Vermaak

VALIDATE Network Manager, University of Oxford

An update on VALIDATE at the end of our second year

1040 Talks by most recently funded round #3 projects:

1040 Prof Myron Christodoulides

University of Southampton, UK

Protective efficacy of conserved Leishmania hypothetical proteins against visceral leishmaniasis (P019)

1053 Dr Barbara Kronsteiner-Dobramysl

University of Oxford, UK

Metabolic reprogramming of skin microenvironment for improved BCG vaccine efficacy (P020)

1106 Dr Sasha Larsen

IDRI, USA

Development of an RNA based vaccine against Mycobacterium tuberculosis (P021)

1119 Dr Elena Stylianou

University of Oxford, UK

Developing a mouse model of diabetes to evaluate vaccines for TB and melioidosis (P022)

1132 Dr Julen Tomás Cortázar

University College Dublin, Ireland

Elucidating the T-cell epitopes and T-cells responses of two B.pseudomallei vaccine agents (P023)

1145 Emilie Karafillakis

LSHTM, UK

Monitoring and addressing challenging risks, rumours and reputations across the GCRF Vaccinology Networks

1200 Lunch

1300 Talks by funded round #1 projects (all now finished):

1300 Sally Hayward

SGUL/LSHTM, UK

Enhancing BCG efficacy: the Social Technology Lab Initiative (P002)

1320 Dr Javier Salguero Bodes

Public Health England (PHE), UK

The effect of BCG vaccination in immune responses against visceral leishmaniasis in a natural (canine) model of infection (P003)

1340 Asst Prof Steve Smith

LSHTM, UK

How do functional and metabolic characteristics of trained monocytes affect their anti-bacterial activity? (P004)

1400 Dr Panjaporn Chaichana

MORU, Thailand

Establishment of a functional assay panel to evaluate the role of antibodies in defence against melioidosis and tuberculosis (P007)

1420 Dr Rajko Reljic

SGUL, UK

Overcoming innate immune tolerance in the respiratory tract for optimal vaccine design (P009)

1440 Dr Bernardo Villarreal-Ramos

APHA, UK

Natural variation of the bovine lymph node microenvironment and its possible effect on BCG immunogenicity (P011)

1500 Tea/coffee break

1530 Keynote speech:

Affiliate Prof Rhea Coler

IDRI, USA

Novel TB and Leprosy Vaccines: from the lab bench to clinical trials (an industry perspective)

1730 Wembley Stadium private tour

VALIDATE has organised a 'behind the scenes' tour of the world-class Wembley Stadium for those who are interested.Highlights include the England dressing room, the press conference facilities, the Royal Box and the players' tunnel. This is at VALIDATE's costs. Find out more about the stadium and it's history in UK sport and entertainment, including hosting the 2012 London Olympics and FA Cup Finals, here.

1900 Dinner

VALIDATE will provide a 'No host' dinner for delegates who would like to participate and network further with other members. This will be at each delegates own cost.

Wednesday 2 October 2019 (morning) - The Grand Hall

0830 Tea/coffee

0900 Talks by funded round #2 projects (which are close to finishing):

0900 Dr Mohamed Osman

University of York, UK

Identification of Leishmania donovani and Mycobacterium tuberculosis - derived proteins on the surface of infected macrophages that are associated with ADCC induction (P012)

0920 Prof Susie Dunachie

University of Oxford, UK

Vaccines to target people with diabetes: characterising the pathways of immune response to M.tuberculosis and B.pseudomallei in people with diabetes compared to non-diabetes (P016)

0940 VALIDATE Fellow talks

0940 Prof Samantha Sampson on behalf of Dr Jomien Mouton

Stellenbosch University, South Africa

Identification of latency associated antigens and biosignatures associated with Mycobacterium tuberculosis

0955 Dr Rachel Tanner

University of Oxford, UK

Characterising the BCG-induced antibody response to inform the design of improved vaccines against M.tuberculosis, M.leprae and M.bovis

1010 Tea/coffee break

1040 Research Funder talks - aiming to help members find future funding opportunities

1040 Prof Helen Fletcher

UKRI/LSHTM, UK

Global Challenges Research Fund (GCRF) and Newton Fund

1100 Dr Peter Hart

Wellcome, UK

Wellcome Vaccines Funding

1120 Dr Martin Broadstock

Medical Research Council (MRC), UK

MRC Funding opportunities

1140 Prof Helen McShane

VALIDATE Director, University of Oxford

Annual Meeting wrap-up

1200 Lunch (where you will be joined by the open Science Conference delegates. The day continues into the VALIDATE-BSI 2019 Scientific Conference 'Vaccine Development for Neglected Intracellular Pathogens.'

To register for the 3rd VALIDATE Annual Meeting, visit our Conference and Annual Meeting webpage. Registration closes 6th September.

Printable version of the Programme:

3rd VALIDATE Annual Meeting Programme.pdf